Oral tolerance induction in experimental autoimmune encephalomyelitis with Candida utilis expressing the immunogenic MOG35-55 peptide

PLoS ONE

Volumn 11, Issue 5, 2016, Pages

  Buerth, Christoph ^a   Mausberg, Anne K ^b   Heininger, Maximilian K ^b   Hartung, Hans Peter ^b   Kieseier, Bernd C ^b   Ernst, Joachim F ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Department of Orthopedic Surgery   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MEMBRANE PROTEIN; GAS1 PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN 35-55; UNCLASSIFIED DRUG; PEPTIDE FRAGMENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; CYBERLINDNERA JADINII; DEMYELINATION; DISABILITY; DISEASE SEVERITY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; FUNGAL STRAIN; FUNGAL VIABILITY; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; MOUSE; MUCOSAL IMMUNITY; MULTIPLE SCLEROSIS; MYELITIS; NONHUMAN; ORAL TOLERANCE; PARALYSIS; REGULATORY T LYMPHOCYTE; AMINO ACID SEQUENCE; ANIMAL; C57BL MOUSE; CANDIDA; CHEMISTRY; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANIMALS; CANDIDA; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; IMMUNE TOLERANCE; MICE; MICE, INBRED C57BL; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; PEPTIDE FRAGMENTS; T-LYMPHOCYTES;

EID: 84968719177     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0155082     Document Type: Article

References (40)

1. Compston A, Coles A. Multiple sclerosis. The Lancet. 2001; 359: 1221-1231. doi: 10.1016/S0140-6736(02)08220-X
2. Gold R. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain. 2006; 129: 1953-1971. doi: 10.1093/brain/awl075 PMID: 16632554
3. Goverman J. Autoimmune T cell responses in the central nervous system. Nature Reviews Immunology. 2009; 9: 393-407. doi: 10.1038/nri2550 PMID: 19444307
4. Mayer L, Shao L. Therapeutic potential of oral tolerance. Nature Reviews Immunology. 2004; 4: 407-419. doi: 10.1038/nri1370 PMID: 15173830
5. Weiner HL. Oral tolerance, an active immunologic process mediated by multiple mechanisms. J Clin Invest. 2000; 106: 935-937. doi: 10.1172/JCI11348 PMID: 11032852
6. Faria AMC, Weiner HL. Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol. 2006; 13: 143-157. doi: 10.1080/17402520600876804 PMID: 17162357
7. Petsch D, Anspach FB. Endotoxin removal from protein solutions. J Biotechnol. 2000; 76: 97-119. PMID: 10656326
8. Ardiani A, Higgins JP, Hodge JW. Vaccines based on whole recombinant Saccharomyces cerevisiae cells. FEMS Yeast Res. 2010; 10: 1060-1069. doi: 10.1111/j.1567-1364.2010.00665.x PMID: 20707820
9. Bitar DM, Whitacre CC. Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein. Cell Immunol. 1988; 112: 364-370. PMID: 2451570
10. Higgins PJ, Weiner HL. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments. J Immunol. 1988; 140: 440-445. PMID: 2447178
11. Maassen CBM, Laman JD, van Holten-Neelen C, Hoogteijling L, Groenewegen L, Visser L, et al. Reduced experimental autoimmune encephalomyelitis after intranasal and oral administration of recombinant lactobacilli expressing myelin antigens. Vaccine. 2003; 21: 4685-4693. PMID: 14585676
12. Kasarello K, Kwiatkowska-Patzer B, Lipkowski AW, Bardowski JK, Szczepankowska AK. Oral Administration of Lactococcus lactis Expressing Synthetic Genes of Myelin Antigens in Decreasing Experimental Autoimmune Encephalomyelitis in Rats. Med Sci Monit. 2015; 21: 1587-1597. doi: 10.12659/MSM.892764 PMID: 26026273
13. Lee SY, Choi JH, Xu Z. Microbial cell-surface display. Trends Biotechnol. 2003; 21: 45-52. PMID: 12480350
14. Müller G. Novel applications for glycosylphosphatidylinositol-anchored proteins in pharmaceutical and industrial biotechnology. Mol Membr Biol. 2011; 28: 187-205. doi: 10.3109/09687688.2011.562557 PMID: 21413835
15. Tanaka T, Yamada R, Ogino C, Kondo A. Recent developments in yeast cell surface display toward extended applications in biotechnology. Appl Microbiol Biotechnol. 2012; 95: 577-591. doi: 10.1007/s00253-012-4175-0 PMID: 22652839
16. Kurtzman C, Fell JW, Boekhout T. The Yeasts. Elsevier; 2011.
17. Rupp O, Brinkrolf K, Buerth C, Kunigo M, Schneider J, Jaenicke S, et al. The structure of the Cyberlindnera jadinii genome and its relation to Candida utilis analyzed by the occurrence of single nucleotide polymorphisms. J Biotechnol. 2015; 211: 20-30. doi: 10.1016/j.jbiotec.2015.06.423 PMID: 26150016
18. Buerth C, Heilmann CJ, Klis FM, de Koster CG, Ernst JF, Tielker D. Growth-dependent secretome of Candida utilis. Microbiology. 2011; 157: 2493-2503. doi: 10.1099/mic.0.049320-0 PMID: 21680638
19. Kunigo M, Buerth C, Tielker D, Ernst JF. Heterologous protein secretion by Candida utilis. Appl Microbiol Biotechnol. 2013; 97: 7357-7368. doi: 10.1007/s00253-013-4890-1 PMID: 23613034
20. Kunigo M, Buerth C, Ernst JF. Secreted xylanase XynA mediates utilization of xylan as sole carbon source in Candida utilis. Appl Microbiol Biotechnol. 2015; 99: 8055-8064. doi: 10.1007/s00253-015-6703-1 PMID: 26051669
21. Tomita Y, Ikeo K, Tamakawa H, Gojobori T, Ikushima S. Genome and transcriptome analysis of the food-yeast Candida utilis. PLoS ONE. 2012; 7: e37226. doi: 10.1371/journal.pone.0037226 PMID: 22629373
22. Kieseier BC, Kiefer R, Clements JM, Miller K, Wells GM, Schweitzer T, et al. Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain. 1998; 121 (Pt 1): 159-166. PMID: 9549496
23. Schreuder MP, Deen C, Boersma WJ, Pouwels PH, Klis FM. Yeast expressing hepatitis B virus surface antigen determinants on its surface: implications for a possible oral vaccine. Vaccine. 1996; 14: 383-388. PMID: 8735548
24. Shin SJ, Bae JL, Cho Y.-W., Lee DY, Kim D.-H., Yang M.-S., et al. Induction of antigen-specific immune responses by oral vaccination with Saccharomyces cerevisiae expressing Actinobacillus pleuropneumoniae ApxIIA. FEMS Immunol Med Microbiol. 2005; 43: 155-164. doi: 10.1016/j.femsim.2004.07.004 PMID: 15681145
25. Kim J.-M., Jung D.-I., Eom YJ, Park S.-M., Yoo H.-S., Jang Y.-S., et al. Surface-displayed expression of a neutralizing epitope of ApxIIA exotoxin in Saccharomyces cerevisiae and oral administration of it for protective immune responses against challenge by Actinobacillus pleuropneumoniae. Biosci Biotechnol Biochem. 2010; 74: 1362-1367. doi: 10.1271/bbb.90941 PMID: 20622458
26. Wasilenko JL, Sarmento L, Spatz S, Pantin-Jackwood M. Cell surface display of highly pathogenic avian influenza virus hemagglutinin on the surface of Pichia pastoris cells using alpha-agglutinin for production of oral vaccines. Biotechnol Prog. 2010; 26: 542-547. doi: 10.1002/btpr.343 PMID: 19950135
27. Bhowmick S, Clark RB, Brocke S, Cone RE. Antigen-specific splenic CD4+ and CD8+ regulatory T cells generated via the eye, suppress experimental autoimmune encephalomyelitis either at the priming or at the effector phase. Int Immunol. 2011; 23: 119-128. doi: 10.1093/intimm/dxq461 PMID: 21273399
28. Farooq SM, Ashour HM. Eye-mediated induction of specific immune tolerance to encephalitogenic antigens. CNS Neurosci Ther. 2013; 19: 503-510. doi: 10.1111/cns.12087 PMID: 23522052
29. Farooq SM, Ashour HM. In vitro-induced cell-mediated immune deviation to encephalitogenic antigens. Brain Behav Immun. 2014; 35: 64-69. doi: 10.1016/j.bbi.2013.09.016 PMID: 24095895
30. Leech MD, Chung C.-Y., Culshaw A, Anderton SM. Peptide-based immunotherapy of experimental autoimmune encephalomyelitis without anaphylaxis. Eur J Immunol. 2007; 37: 3576-3581. doi: 10.1002/eji.200737148 PMID: 18000952
31. De Jesus M, Rodriguez AE, Yagita H, Ostroff GR, Mantis NJ. Sampling of Candida albicans and Candida tropicalis by Langerin-positive dendritic cells in mouse Peyer's patches. Immunol Lett. 2015; 168: 64-72. doi: 10.1016/j.imlet.2015.09.008 PMID: 26386376
32. Pabst O, Mowat AM. Oral tolerance to food protein. Mucosal Immunol. 2012; 5: 232-239. doi: 10.1038/mi.2012.4 PMID: 22318493
33. Mausberg A.-K., Jander S, Reichmann G. Intracerebral granulocyte-macrophage colony-stimulating factor induces functionally competent dendritic cells in the mouse brain. Glia. 2009; 57: 1341-1350. doi: 10.1002/glia.20853 PMID: 19229994
34. Croxford AL, Spath S, Becher B. GM-CSF in Neuroinflammation: Licensing Myeloid Cells for Tissue Damage. Trends in Immunology. 2015; 36: 651-662. doi: 10.1016/j.it.2015.08.004 PMID: 26431942
35. Bhattacharya P, Thiruppathi M, Elshabrawy HA, Alharshawi K, Kumar P, Prabhakar BS. GM-CSF: An immune modulatory cytokine that can suppress autoimmunity. Cytokine. 2015; 75: 261-271. doi: 10.1016/j.cyto.2015.05.030 PMID: 26113402
36. Whitacre CC, Gienapp IE, Orosz CG, Bitar DM. Oral tolerance in experimental autoimmune encephalomyelitis. III. Evidence for clonal anergy. J Immunol. 1991; 147: 2155-2163. PMID: 1717550
37. Melamed D, Friedman A. Direct evidence for anergy in T lymphocytes tolerized by oral administration of ovalbumin. Eur J Immunol. 1993; 23: 935-942. doi: 10.1002/eji.1830230426 PMID: 8458379
38. Miller A, Lider O, Roberts AB, Sporn MB, Weiner HL. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. Proc Natl Acad Sci USA. 1992; 89: 421-425. PMID: 1370356
39. Rizzo LV, Morawetz RA, Miller-Rivero NE, Choi R, Wiggert B, Chan CC, et al. IL-4 and IL-10 are both required for the induction of oral tolerance. J Immunol. 1999; 162: 2613-2622. PMID: 10072503
40. Millington OR, Mowat AM, Garside P. Induction of bystander suppression by feeding antigen occurs despite normal clonal expansion of the bystander T cell population. J Immunol. 2004; 173: 6059-6064. PMID: 15528341